Sasanka Chakrabarti

InstitutionMaharishi Markandeshwar (deemed to be) University
AddressHaryana.
India
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 9 Covid-19 publications, with a maximum of 2 publications in April 2021
    All Publications
    Bar chart showing 45 publications over 16 distinct years, with a maximum of 6 publications in 2014
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chakrabarti S, Chakrabarti SS, Kaur U, Agrawal BK, Ganguly U, Jin K. Cross-immunity and trained immunity in explaining variable COVID-19 mortality-Guidance for future pandemics. J Med Virol. 2021 Jul; 93(7):4094-4096. PMID: 33755226.
      Citations:    Fields:    Translation:HumansAnimalsPHPublic Health
    2. Banerjee A, Ganguly U, Saha S, Chakrabarti S, Saini RV, Rawal RK, Saso L, Chakrabarti S. Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits. Expert Rev Anti Infect Ther. 2021 Oct; 19(10):1245-1258. PMID: 33739215.
      Citations: 1     Fields:    Translation:Humans
    3. Saha S, Chakrabarti S, Singh PK, Poddar J, Satapathi S, Saini S, Kakar SS, Roy P. Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension. Stem Cell Rev Rep. 2021 02; 17(1):132-143. PMID: 32748331.
      Citations: 1     Fields:    Translation:HumansCells
    4. Kaur U, Chakrabarti SS, Ojha B, Pathak BK, Singh A, Saso L, Chakrabarti S. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Curr Drug Targets. 2021; 22(2):192-201. PMID: 32972339.
      Citations: 8     Fields:    Translation:Humans
    5. Chakrabarti SS, Kaur U, Singh A, Chakrabarti S, Krishnatreya M, Agrawal BK, Mittal A, Singh A, Khanna R, Gambhir IS, Jin K, Chakrabarti S. Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India. Aging Dis. 2020 Dec; 11(6):1339-1344. PMID: 33269091.
      Citations: 6     
    6. Kaur U, Acharya K, Mondal R, Singh A, Saso L, Chakrabarti S, Chakrabarti SS. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. Eur J Pharmacol. 2020 Nov 15; 887:173545. PMID: 32926917.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
    7. Parashar NC, Poddar J, Chakrabarti S, Parashar G. Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2. Infect Genet Evol. 2020 11; 85:104497. PMID: 32791240.
      Citations: 4     Fields:    Translation:HumansCells
    8. Chakrabarti SS, Kaur U, Banerjee A, Ganguly U, Banerjee T, Saha S, Parashar G, Prasad S, Chakrabarti S, Mittal A, Agrawal BK, Rawal RK, Zhao RC, Gambhir IS, Khanna R, Shetty AK, Jin K, Chakrabarti S. COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity? Aging Dis. 2020 May; 11(3):480-488. PMID: 32489695.
      Citations: 14     
    9. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020 Apr; 11(2):216-228. PMID: 32257537.
      Citations: 440